Voltaren News and Research

RSS

Voltaren is a drug that is used to treat the symptoms of rheumatoid arthritis and is being studied in the prevention and treatment of some types of skin cancer. It blocks substances that cause inflammation and pain. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of cyclooxygenase inhibitor, a type of nonsteroidal anti-inflammatory drug (NSAID), and a type of antiangiogenesis agent. Also called diclofenac sodium.

Combined approach needed to address oral health inequalities and systemic health burden

'Time to put your money where your mouth is: addressing inequalities in oral health' is the new Economist Impact white paper published today, commissioned by the EFP (European Federation of Periodontology) with support from Haleon.

13 Feb 2024

BodyGuard wearable patch product shows superiority to common NSAID treatments in restoring joint function

Perth skin science technology company OBJ Limited is set to revolutionise treatment of joint injuries and osteoarthritis after its BodyGuard wearable patch product proved its superiority to the world-leading non-steroidal anti-inflammatory drug product Voltaren.

31 Mar 2016

New review points to most promising areas for liposomes' further development

An international group of scientists, including Vladimir Chupin, head of the Biophysics Section at MIPT, and Vladimir Torchilin (Northeastern University, the USA), one of the world's leading experts in pharmacology, recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.

11 Aug 2015

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International plc today reported fourth quarter 2014 revenues of $800 million, an increase of 37 percent compared to fourth quarter 2013 revenues of $585 million, including new product revenue from 2014 strategic M&A transactions.

2 Mar 2015

Endo International revenues increase $719M to 1% in Q2 2014

Endo International plc today reported second quarter 2014 revenues of $719 million, an increase of 1 percent compared to second quarter 2013 revenues of $712 million.

31 Jul 2014

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Endo Health Solutions today reported fourth quarter 2013 revenues of $585 million, compared to $750 million for the same quarter of 2012.

28 Feb 2014

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.

3 May 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

6 Jan 2012

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

Painkillers and heart attack risk

A new study has shown that taking certain commonly used painkillers for long periods or in high doses increases the risk of heart attacks or strokes. The study comes from researchers from Bern University and is published in the British Medical Journal.

16 Jan 2011

Endo third quarter total revenues increase 23% to $444.1 million

Endo Pharmaceuticals today reported financial results for the third quarter 2010.

1 Nov 2010

Stroke risk with common pain killers dismissed by manufacturer

An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, “it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day.”

14 Sep 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

Endo acquires HealthTronics

Endo Pharmaceuticals announced today the completion of its acquisition of HealthTronics, Inc., a leading U.S. provider of urological products and services, located in Austin, Texas.

15 Jul 2010

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo Pharmaceuticals today announced the successful completion of the tender offer by its wholly owned subsidiary, HT Acquisition Corp., for all of the outstanding shares of common stock of HealthTronics, Inc..

3 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010